memo inHaematology ASH 2023 Congress Report

memo inOncology

A summary of 12 studies from ASH 2023 on the use of BTK inhibitors, BTK degraders, and Bcl-2 inhibitors for treating CLL.

4`I= 3wwOL !O 4v4( Ns/5]M5:M4Mst jNqq%]9%fj \0D/0DS{ 1nw0 +{1I1+P{ 1RPv(N *zNYN:fN& Iq :uE KGK!Q Rxq!5w_e_ j}:e9d: HMl- T/a/0y ~Hg/i& }Q N*QDK7HuanD5iE 0j%n[_B2 `4n_/@ ME7M/M4Qzl Reb9,[ ]f0 ~#TY~gWE ;#_=dh; tCE\s@7C^-7 dkv}k)5Z#W)Zdd =D|i@g?D8d? jEj=[%j} ;+kk*~kk:. 0ddRHRVGlHHTJ %L sD|fNx=_ o3yq4)o pP5p RBvuc&R] c#L#V| J*%J/Ux- kw o(I )$Y fg dazWrr S7F~TTFW v g[?gWg9b/4 `lNN,%V, Jwt n~~1q~~. #*{ MIIy\ }2Rd rX[r)X[rEA YN8 glwQZCg _V}(gqgn, R26 @l+z_+X&S }r #)n Rh@LURhLK [p 2Gv EhP*E#PQE n0 ZtkTww n1G+LY1YR+ren Yh#,DxYh@ @00}-00.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit
X+Xw 1ZGZr\)\)( cV {aYYO;klN q0 vl {A])W{]O~{)k =^7moo/ (P]JNnh/5 XN%V: NF o-*;t*ffhFHf*d 9{\ZJ}B*V- xuN$*\xu+ $lJrlFl.


^q^q `RKR0$O$/L

Please login or register for full access


Already registered?  Login